Skip to main content

Lupus

Plaquenil.HCQ_.pills_.jpg (keep)

Prolonging the Controversy of Hydroxychloroquine

Nov 30, 2021

Since the start of the pandemic, hydroxychloroquine (HCQ) was forced into the limelight for the prevention/treatment of COVID-19. When it was found to be ineffective for COVID-19 and might cause potential harm, the drug came under closer scrutiny for its safety profile.

Read Article
Sle.vote_.criteria.png

DORIS - Defining Remission in Lupus

Nov 29, 2021

Proponents of treat to target in systemic lupus erythematosus (SLE) have all agreed that "remission" should be the goal, but defining remission may be tricky in SLE.  A SLE Definitions Of Remission (DORIS)Task Force was convened in 2015 and first published their work in 2016. Now the 2021

Read Article
IL-35 (blood and urine) is elevated in #SLE pts with nephritis. Small study of 42 SLE pts serum IL-35 had 90% sensitivity & 65% specificity while urine IL-35 had 86.4% sensitivity and 75% specificity to establish the diagnosis of LN https://t.co/pK1rVCQQr9

Dr. John Cush @RheumNow( View Tweet )

Nov 29, 2021
ICYMI: Data on Existing SLE Medications, Patient Centered Outcomes, and Exercise: Dr. Michelle Petri discusses data on existing SLE medications, patient-centered outcomes and the importance of exercise, presented Monday at the #ACR21 annual meeting.https://t.co/SQOLQRmQtp https://t.co/ZA1uISdGyk
Dr. John Cush @RheumNow( View Tweet )
Nov 28, 2021
ICYMI: Update on Safety, Effectiveness of SARS-CoV-2 vaccines in SLEhttps://t.co/ihWapOaiNO https://t.co/daoIZtpsHH
Dr. John Cush @RheumNow( View Tweet )
Nov 28, 2021
SLE and Health-Related Quality of Life: Dr. Sheila Reyes ( @RHEUMarampa) discusses abstract #1261 presented at the #ACR21 annual meeting.https://t.co/yLPBfId6tL https://t.co/09U4nUT9c7
Dr. John Cush @RheumNow( View Tweet )
Nov 24, 2021
FDA Session Review: Dr. Arthur Kavanaugh discussed the FDA session presented at the ACR21meeting, including safety data and new approvals and indications in several rheumatic diseases, including lupus, ANCA-associated vasculitis, lupus nephritis and more.https://t.co/5YkbzDv0YR https://t.co/MS9KNIfm2m
Dr. John Cush @RheumNow( View Tweet )
Nov 24, 2021
covid vaccine needle vaccination

Update on Safety, Effectiveness of SARS-CoV-2 vaccines in SLE

It is almost a year since the Pfizer-BioNTech SARS-CoV-2 vaccine has been made available by the FDA under emergency use authorization (EUA). The question still being asked is whether the vaccine is safe for people with lupus? 



It is worth noting that the Phase III randomised

Read Article
ICYMI: Type 1 and Type II Lupus — Patient Perspectives: Dr. Mehta ( @bella_mehta) interviews Dr. Clowse about abstract #1277 presented at the #ACR21 annual meetinghttps://t.co/2w1Lwwhplf https://t.co/4sJR6DG0q0
Dr. John Cush @RheumNow( View Tweet )
Nov 22, 2021
Frailty in Lupus: Dr. Sheila Reyes ( @RHEUMarampa) reviews abstract #0869 presented at the #ACR21 annual meeting.https://t.co/5jR74VQBeG https://t.co/AJIhR5Waip
Dr. John Cush @RheumNow( View Tweet )
Nov 19, 2021
Vitamin D and Hydroxychloroquine Studies: Dr. Michelle Petri discussed studies regarding Vitamin D supplementation and as well as data on hydroxychloroquine that was presented Saturday at the #ACR21 annual meeting.https://t.co/CU8wFVYhNg

Dr. John Cush @RheumNow( View Tweet )

Nov 17, 2021
Hydroxychloroquine Levels in Type I and 2 Lupus: Bella Mehta ( @bella_mehta) interviews Dr. Megan Clowse about abstract #0877, presented at the #ACR21 annual meeting.https://t.co/L62iO8J9QF https://t.co/Oy58jbPPts
Dr. John Cush @RheumNow( View Tweet )
Nov 15, 2021
Treat to Target in SLE: Dr. Yuzaiful Yusof ( @Yuz6Yusof ) reviews abstract #0865 presented at the #ACR21 annual meeting.https://t.co/THX4nLWCaR https://t.co/951HAdkONi
Dr. John Cush @RheumNow( View Tweet )
Nov 15, 2021
covid coronavirus virus

More severe COVID-19 outcomes in African American, Hispanic individuals with SLE

A study from ACR21 convergence discussing data from the Global Rheumatology Alliance (GRA) describes the association between race/ethnicity on COVID-19 outcomes specifically in lupus patients.

Read Article
ICYMI: Watch: Lupus Updates: Dr. Michelle Petri Dr. Michelle Petri offers perspective and insight into lupus related data presented Saturday at the #ACR21 annual meeting.https://t.co/nluRreQPT1 https://t.co/fzm1RW6Rpy
Dr. John Cush @RheumNow( View Tweet )
Nov 13, 2021
DPGN, lupus, nephritis, GN, glomerulonephritis, biopsy, kidney

Racial/ethnic disparity in U.S. lupus nephritis mortality

At #ACR21, the plenary session included an analysis of deaths from SLE throughout the US comparing 1999 to 2019 (Abstract #0454).

Read Article
Sign

Emapalumab for the treatment of macrophage activation syndrome

Macrophage activation syndrome (MAS) is a term commonly used by rheumatologists to describe a potentially life-threatening complication of systemic inflammatory disorders, most commonly occurring in people with systemic juvenile idiopathic arthritis (sJIA) and systemic lupus erythematosus (

Read Article
Lupus Day 2 Highlights: Drs Dao , Mehta, Yusof, Pope, Reyes and Castillo review lupus-related information and data presented during day 2 of the #ACR21 annual meeting.https://t.co/QX6Ay77FKo@KDAO2011 @bella_mehta @Yuz6Yusof @Janetbirdope @RHEUMarampa @_Castillo_Pedro https://t.co/ldAHqXsi0G
Dr. John Cush @RheumNow( View Tweet )
Nov 12, 2021
ACR Best

ACR21 Best Abstracts - Day 4

Nov 10, 2021

On the last day of ACR21 Annual Meeting, the RheumNow faculty selected these 15 as their favorite reports.

Read Article
Malar,rash,SLE, Lupus

Predictors of Remission and Low Disease Activity in SLE

Nov 10, 2021

A treat-to-target strategy has been shown to improve clinical outcomes in patients with rheumatic diseases like rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis including systemic lupus erythematosus.  The goal of treatment in SLE is aimed at remission or low disease activity

Read Article
#ACR21 The Great Debate: Belimumab vs Voclosporin as Add-On Therapy in #LupusNephritis | Dr. Petri & Dr. Rovin Audience Vote 🗳: What would you add to mycophenolate first? Belimumab 71%, Voclosporin 29% #ACRAmbassador @ACRheum Summary of Pros & Cons of Each⬇️ https://t.co/OtLxs8IYr9
Mithu Maheswaranathan, MD @MithuRheum( View Tweet )
Nov 09, 2021
#ACR21 TM26. Familial chilblains lupus seen in genetic mutation in Three Prime Repair Exonuclease 1 (TREX1). Suspected due to onset in infancy. @Rheumnow https://t.co/ZryOpeoJT8 https://t.co/LqZqoGDAL2
Nov 09, 2021
Update on Safety, Effectiveness of SARS-CoV-2 vaccines in SLE from Dr. Yuz Yusof ( @Yuz6Yusof) It's almost a year since the Pfizer-BioNTech SARS-CoV-2 vaccine has been made available by the FDA under EUA. But is the vaccine safe for people with lupus?https://t.co/i3HeCvS6El https://t.co/Tn0nWKrK4T
Dr. John Cush @RheumNow( View Tweet )
Nov 09, 2021
GRA @rheum_covid data presented by @mugartegil. African-American and Hispanic individuals with SLE have MUCH worse COVID-19 outcomes. Likely related socioeconomic and health disparities. Abstr#1933 #ACR21 @RheumNow https://t.co/YUoOeIxN7O
Richard Conway @RichardPAConway( View Tweet )
Nov 09, 2021
#ACR21 #Abstr1909 📢We need to stress the importance of hydroxychloroquine adherence to our patients. Adherence (>90% of the time) reduced premature CVD mortality by 52% in #rheumatoidarthritis and #lupus. The study didn’t adjust for smoking @RheumNow https://t.co/D9pGqwWhje https://t.co/R6r3cSexUB
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Nov 09, 2021
×